XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue        
Revenue $ 1,530 $ 4,525 $ 2,030 $ 9,375
Cost of goods sold        
Cost of goods sold 207 1,360 420 3,664
Gross margin 1,323 3,165 1,610 5,711
Operating expenses:        
Research and development 10,394 9,254 17,214 13,888
General and administrative 3,023 4,516 4,337 5,981
Total operating expenses 13,417 13,770 21,551 19,869
Loss from operations (12,094) (10,605) (19,941) (14,158)
Other income (loss):        
Interest income 241 123 343 232
Other expense (119) (2) (119) (11)
Foreign exchange (loss) gain (2,280) 793 (990) 1,202
Total other (loss) income (2,158) 914 (766) 1,423
Loss before income taxes (14,252) (9,691) (20,707) (12,735)
Benefit for income taxes 2,608 4,573 3,668 5,049
Net loss $ (11,644) $ (5,118) $ (17,039) $ (7,686)
Net loss per share—basic and diluted (in dollars per share) $ (0.38) $ (0.17) $ (0.56) $ (0.26)
Shares used to compute basic and diluted net loss per share (in shares) 30,439,277 29,987,917 30,439,277 29,707,352
Manufacturing Revenue [Member]        
Revenue        
Revenue $ 1,530 $ 4,500 $ 2,030 $ 9,000
Cost of goods sold        
Cost of goods sold 207 1,341 420 3,376
Clinical Trial Service Revenue [Member]        
Revenue        
Revenue 0 25 0 375
Cost of goods sold        
Cost of goods sold $ 0 $ 19 $ 0 $ 288